Vesalius Biocapital is a European life sciences venture capital investor. The active fund Vesalius Biocapital III had a final closing in May 2019 with € 120 million in commitments.

We are investing in appealing, later-stage companies in drug development, medical devices & diagnostics and eHealth / mHealth, predominantly in Europe. Our portfolio companies address unmet medical & market needs and operate on the basis of strong intellectual property protection.